Meanwhile, EMBRACE-HF and DEFINE-HF showed that there was no difference between empagliflozin/dapagliflozin and placebo in change for KCCQ-CSS or improvement of ≥ 5 points in KCCQ-OS or at least a 20% reduction in NT-proBNP in male or female. The gene discussed is NPPB; the disease is hydrops fetalis.